Hamilton-based biopharmaceutical firm Kiniksa Pharmaceuticals is dedicated to finding, acquiring, developing and distributing therapeutic drugs aimed at treating patients suffering from debilitating diseases around the world. Its product portfolio includes ARCALYST, which targets heart disorder pericarditis; Mavrilimumab, a monoclonal antibody inhibitor for giant cell arteritis; Vixarelimab, a monoclonal antibody for chronic skin inflammation; and KPL-404, a monoclonal antibody inhibitor that targets CD40-CD154 interaction. Established in 2015, the company's mission is to meet significant unmet medical needs in the market.